Zai Lab LTD Form 4 insider transactions

Yajing Chen, Chief Financial Officer of Zai Lab Ltd, sold 619 shares of common stock on August 11, 2026 for $25.00 per share.

Zai Lab Ltd. Director Richard Gaynor acquired American Depositary Shares (ADSs) under a pre-arranged trading plan, indicating continued confidence in the company.

Zai Lab Ltd. reports on changes in beneficial ownership for Chairperson & CEO Du Ying, involving the acquisition and disposition of American Depositary Shares.

Zai Lab Ltd. reports changes in beneficial ownership for Chairperson & CEO Du Ying, including acquisition of shares upon RSU vesting and subsequent sale to cover taxes.

Zai Lab Ltd. reports Chief Legal Officer Titus F. Edmondson III's transactions involving the acquisition of American Depositary Shares upon RSU vesting and subsequent sale to cover taxes.

Zai Lab Ltd. reports changes in beneficial ownership for Chairperson & CEO Du Ying, involving acquisition and sale of American Depositary Shares.

Zai Lab Ltd. reports on changes in beneficial ownership for its Chief Financial Officer, Yajing Chen, involving the acquisition of shares upon RSU vesting and subsequent sale to cover taxes.

Zai Lab Ltd. Director William Lis reported a sale of 7,040 American Depositary Shares (ADS) for $18.09 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Zai Lab Ltd reports the grant of stock options and restricted stock units to Operating Partner Yizhe Wang, with vesting commencing in May 2027.

Zai Lab Chairperson and CEO Ying Du transferred a total of 107,700 American Depositary Shares to trusts for the benefit of her adult son.

Zai Lab Ltd. reports insider trading activity by CEO Du Ying, involving the sale of American Depositary Shares under a pre-arranged Rule 10b5-1 trading plan.

Zai Lab Ltd. Director Du Ying reported transactions involving the sale of American Depositary Shares (ADSs) under a pre-arranged 10b5-1 trading plan.

Chief Legal Officer Frazor Titus Edmondson III sold 3,517 American Depositary Shares of Zai Lab Ltd via a 10b5-1 plan.

Zai Lab Chairperson and CEO Du Ying exercised 100,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Zai Lab Ltd. reports a transaction where President and COO Joshua L. Smiley sold American Depositary Shares to cover taxes upon vesting of Restricted Share Units.

Zai Lab Ltd. reports a transaction where Chief Legal Officer Titus Edmondson Frazor III sold American Depositary Shares to cover taxes upon vesting of Restricted Share Units.

Zai Lab Ltd. reports a transaction where Director Du Ying sold American Depositary Shares to cover tax obligations upon vesting of Restricted Share Units.

Zai Lab Ltd. Chief Financial Officer Yajing Chen sold American Depositary Shares (ADSs) to cover taxes upon vesting of Restricted Share Units.

Zai Lab Ltd. reports a transaction where an insider sold American Depositary Shares to cover taxes upon the vesting of Restricted Share Units.

Zai Lab Ltd. executive Joshua L. Smiley reported transactions involving American Depositary Shares (ADSs) and equity awards, including the acquisition of shares upon vesting of Restricted Share Units and Performance-Based Share Units, and the sale of some shares to cover taxes.

Zai Lab Ltd. Chief Legal Officer, Edmondson Frazor Titus III, reported transactions involving American Depositary Shares (ADSs) acquired through vesting of Restricted Share Units (RSUs) and Performance-Based Share Units (PSUs), with a portion of ADSs sold to cover taxes.

Zai Lab Ltd. reports changes in beneficial ownership for Director Du Ying, including share acquisitions and disposals.

Zai Lab Ltd. Chief Financial Officer, Chen Yajing, has reported a series of transactions involving American Depositary Shares (ADSs) and equity awards.

Rafael Amado, an officer at Zai Lab Ltd, reported transactions involving American Depositary Shares, including acquisitions upon vesting of RSUs and PSUs, and a disposition to cover taxes.

Zai Lab's President and COO, Joshua L. Smiley, reported the acquisition of stock options and restricted share units, alongside the vesting and subsequent tax-related sale of American Depositary Shares.

Zai Lab's Chief Legal Officer reported new equity grants, RSU vesting, and a tax-related sale of American Depositary Shares.

Zai Lab's Chief Financial Officer, Chen Yajing, reported new grants of stock options and restricted share units, alongside a sale of American Depositary Shares to cover tax obligations.

Zai Lab's President of Global Oncology R&D, Rafael Amado, reported new equity grants and a tax-related sale of American Depositary Shares.

Zai Lab's Chairperson and CEO, Du Ying, received significant equity grants, including stock options and restricted share units, on March 11, 2026.

Zai Lab's Chairperson and CEO, Du Ying, executed planned transactions including option exercises, RSU vestings, and tax-related share sales under a Rule 10b5-1 plan.